Intellia Therapeutics Inc (NTLA)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$8.06

Buy

$8.12

arrow-up$0.195 (+2.47%)

Prices updated at 16 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
NASDAQ
arrow-down-0.18%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Frank Verwiel, M.B.A.,M.D.
CEO
Dr. John M. Leonard, M.D.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
598
Head office
40 Erie Street
Cambridge
United States
02139
mobile
+1 857 285-6200
letter
lina.li@intelliatx.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Ms. Birgit Schultes
Executive Vice President and Chief Scientific Officer
-
Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
Independent Director
0.06m
Dr. John M. Leonard, M.D.
Director, President and Chief Executive Officer
0.69m
Dr. Frank Verwiel, M.B.A.,M.D.
Chairman of the Board
0.10m
Mr. Brian Goff
Independent Director
0.03m
Mr. William J. Chase
Independent Director
0.08m
Dr. Jesse Goodman, M.D.,M.P.H.
Independent Director
0.06m
Dr. Georgia Keresty, M.P.H.,PhD
Independent Director
0.07m
Mr. James Basta, J.D.
Executive Vice President, General Counsel and Corporate Secretary
0.48m
Dr. David Lebwohl, M.D.
Executive Vice President and Chief Medical Officer
0.52m
Mr. Edward J. Dulac, III
Treasurer, Executive Vice President and Chief Financial Officer
0.23m
Ms. Muna Bhanji, Ph.
Independent Director
0.07m
Ms. Eliana Clark
Executive Vice President and Chief Technology Officer
-
Mr. Michael P. Dube
Vice President and Chief Accounting Officer
0.36m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
ARK Investment Management LLC13,011,015
Vanguard Group Inc10,752,031
BlackRock Inc10,556,190
ARK Disruptive Innovation Full Composite8,704,122
ARK Innovation ETF8,483,715

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
02 Oct 2024-
22 Jul 2024-
22 Jul 2024-
01 Jul 2024-
01 Jul 2024-
17 Jun 2024-
13 Jun 2024-
13 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
12 Jun 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.